SYNOPSIS A small group of tests is proposed for the rapid investigation of acute bleeding states. These techniques are within the compass of many clinical laboratories, and the whole scheme may be run through in one to one-and-a-half hours.
Acute bleeding states may arise in association with concealed accidental haemorrhage and other obstetrical complications, surgery of the lung, carcinomatosis, and other conditions. It is characteristic for multiple haemostatic defects to be produced, the pattern varying from case to case. If the haematologist is to contribute to clinical management he must be able quickly to identify the cause of bleeding so that he may be able to advise promptly on the appropriate replacement therapy or on the risks of surgery.
The following scheme of investigation is therefore offered for a rapid appraisal of those facets of haemostasis which usually seem to be affected. A fuller discussion has been given by Ingram, Norris, and Tanner (1960) with an illustrative obstetrical case history; an example from chest surgery has been described by Ingram and Mann (1959) .
The two commonest processes underlying acute failures of haemostasis appear to be defibrination and fibrinolysis; it has been thought that either may be initiated by an escape of tissue material into the blood stream. More rarely, a heparin-like inhibitor may appear in the blood.
Defibrination and fibrinolysis may occur separately or together. Their effects are similar, for they both characteristically produce thrombocytopenia, fibrinogenopenia, and deficiencies of antihaemophilic globulin (AHG) and factor V. The following scheme is therefore designed to test these four components, as well as to detect fibrinolysis and heparinaemia. The other types of inhibitors which have been described do not appear to develop so acutely (with the possible exceptions of one associated with fibrinolysis described by Niewiarowski, Kowalski, Received for publication 30 March 1961. and Stachurska, 1959 , and of the effect discussed by von Kaulla and Swan, 1958) .
A few notes on treatment are appended.
METHODS
All tests except the platelet count are made on citrated plasma (9 volumes of blood added to 1 volume 3-8% sodium citrate). The following five tests are used: (1) Platelet count; (2) Quick's prothrombin time for activity of factor V (a long prothrombin time due to factor V deficiency would be shortened by the addition of Al(OH),-treated normal plasma 1 in 5 or 1 in 10); (3) rapid fibrinogen determination; (4) a simple modification of the thromboplastin generation screening test of Hicks and Pitney (1957) for antihaemophilic globulin activity (although also affected by factor V); (5) the thrombin clotting time, providing a fibrinogenolysis test (adapted from Wilhelm, Miles, and MacKay, 1955) , and a simple test for heparinaemia. Tests (1) and (2) are, of course, done by the usual methods. Tests (3), (4), and (5) are described below.
TEST 3 This is the determination of the weight of fibrin obtained on clotting a measured volume of plasma (Ingram, 1952a) , omitting drying the clot in hot air. Method Equal volumes of plasma and M/40 CaC12 (say 2-0 ml.) are mixed and incubated for about 10 minutes, a wooden applicator stick being placed in the tube. When a firm clot has formed this is wound on to the stick, expressing the serum. The stick is then transferred to a tube of water and the serum returned to incubate in case further clot forms, which is harvested as before. The total clot is then peeled off the stick (like stripping the rubber grip off the handle of a cricket bat) and pressed between filter papers, and then transferred to acetone, to dry and harden, for exactly 10 minutes. After decanting, the clot is transferred to the warm hand, and the remaining acetone rapidly evaporated by gentle blowing; the clot is then immediately weighed to the nearest 0 2 mg. 356 A suggested schedule for the rapid investigation of acute haemdstatic failuire
The clot may of course be determined by other methods if preferred, but gravimetry has been found very convenient for a 24-hour service, since a chemical balance requires no 'warming up' and most laboratory workers are familiar with its use.
Weight of clot concentration of fibrinogen in Volume of plasma citrated plasma e.g., 723
mg.
0-35 g./100 ml. (the conventional unit) eg,2-1 ml.
Errors The true value will be overestimated by the water remaining in the clot, and underestimated by the dilution of the plasma with the citrate. These errors may be corrected as follows: (a) For retained water, reduce the observed weight of the clot by subtracting 15 % plus an additional J % per mg. observed weight. (This correction was determined empirically by observing the further loss in weight which occurred after heating clots in hot air as described in the original method.) (b) For citrate dilution, multiply the value of the concentration of fibrinogen (as amended by (a) above) per millilitre of plasma by
Percentage plasma in citrated blood Percentage plasma minus percentage citrate (Since the proportion of citrate in the whole citrated blood is known, the correction may be calculated from the haematocrit of this blood.) Note that these corrections tend to cancel each other, and that in fibrinogenopenia, when a very small clot is obtained, they have a small effect anyway and so for clinical purposes they may often be ignored.
The following is an example when the haematocrit of the citrated blood is 34% 100 -34 -66 % x 7-3 -4%; 15% + 4% = 19% 19% of 7-3 -14mg.; 73 -14 = 5-9 mg. 5-9 mg. 66 corrected value -22ml x 66-10 0-32 g./100 ml.
To estimate a patient's plasma fibrinogen deficit, reckon the blood volume as 1/10 body weight; calculate the plasma volume from this estimate and the venous haematocrit; multiply the value obtained by the observed fibrinogen concentration and this gives an estimate of the total plasma fibrinogen. Similarly calculate the total plasma fibrinogen had the concentration been normal (say 0 3 g./100 ml.). The difference between these two calculated values estimates the plasma fibrinogen deficit.
TEST 4 Hicks and Pitney's (1957) test may be reduced to its simplest terms by adopting the 'running' design suggested by Biggs, Eveling, and Richards (1955) . The method is described here in detail and outlined in Table I . Method Mix 0-1 ml. of each of a platelet substitute (see below), control plasma 1 in 10, and M/40 CaCl, and put to incubate with a pipette standing in the tube. One minute later mix 0-1 ml. platelet substitute, 0-1 ml. of patient's plasma 1 in 10, and 0-1 ml. of M/40 CaCI2 in a second tube and put to incubate with a pipette in the tube. Again, one minute later, mix 0-1 ml. of platelet substitute, 0 05 ml. of normal plasma 1 in 10 and 0-05 ml. patient's plasma 1 in 10, and 0-1 ml. M/40 CaCI2, and put to incubate, with a pipette, in a third tube. At the next minute transfer 01 ml. from the first tube to 0-1 ml. of normal citrated plasma to which 01 ml. of M/40 CaCl2 has just been added (5 to 10 sec. before) and measure the clotting time. At the next minute perform this procedure on the second tube and at the next minute for the third tube. At the following three minutes repeat the procedure again for the first, second, and third tubes in that order. It is convenient to arrange the three reaction tubes and six clotting time tubes (containing normal plasma) in the water bath before starting the test. It will be apparent that this procedure yields a three-minute and a sixminute sample by the Hicks and Pitney procedure for normal plasma. the patient's plasma, and a mixture of the two so that in one run it becomes apparent whether the patient's plasma behaves abnormally in this test and if so whether this is due to a deficiency (when the resu'ts from the third tube will approximate to those of the first) or to an inhibitor (in which case the results of the third tube will approximate to those of the second). For confirmation the whole procedure may be repeated in the reverse order, i.e., 50 : 50 mixture, patient's plasma, control plasma, thus obtaining two replicate readings at each sampling time from each tube. The reversal of the order represents an attempt to eliminate a trend due to the passage of time (Ingram, 1955) .
above test is conveniently rapid and adequate to detect gross defects but it ignores differences in the degree of 'contact' to which the plasmas have been subjected. Variations between the 'contacting' of the samples may lead to variations in the rate of their reactivity, and may thus blurr the differences between normal and mildly abnormal plasmas. It is difficult to ensure that contact is equally prevented in all samples but an equal, vigorous contacting can be applied by a brief preincubation with kaolin (Margolis, 1957 (Margolis, , 1958 If the test suggests that the patient's plasma is deficient rather than inhibitory do another run in which the control plasma only has been adsorbed with alumina (Biggs and Macfarlane, 1957, pp. 387, 388) (Brafield and Case, 1956 TEST 5 Fibrinolysin acts in the body as a fibrinogenolysin, and this is also the basis of the test described by Wilhelm et al. (1955) . Separate samples of the patient's and the control plasmas, e.g., 2-0 ml., are incubated concurrently, and at intervals 0-1 ml. samples are withdrawn and the thrombin clotting times measured. If the fibrinogen is being gradually destroyed in the patient's incubated sample the thrombin clotting times on this plasma will progressively lengthen.
Thrombin clotting time test Human thrombin is diluted with M/80 CaCl2 so that when 0-2 ml. is added to 0-1 ml. of normal citrated plasma the clotting time is approximately 10 sec. This test is also sensitive to the presence of heparin so that if readings are obtained from the two plasmas immediately they are put to incubate and the patient's plasma gives a longer clotting time ab initio, this might be due to a heparin-like anticoagulant or to a pre-existing reduction in the fibrinogen concentration of the plasma. If the clotting time is prolonged by heparin, the difference between the patient's and the control times will be reduced by adding to each plasma a volume of toluidine blue solution 1 in 1,000 to 1 in 10,000 before repeating the test; if the long clotting time is due to hypofibrinogenaemia, it will similarly be shortened by adding a volume of fibrinogen solution, approximately 200 mg. per 100 ml. Heparinaemia is, of course, rare, and once this has been excluded, proceed with the fibrinogenolysis test by measuring the thrombin clotting time on further 0-1 ml. subsamples from each plasma at intervals of, say five, 10, 20, 40, and 60 minutes according to the rate of change observed. If the fibrinogen concentration is already low in the patient's sample, fibrinogen must be added to both incubated plasmas in order to work this test, but either way, if no consistent difference between the plasmas is apparent after two hours' incubation, the test is negative for clinical purposes. Note that the control clotting time may also lengthen somewhat as the test proceeds, but this is immaterial, since the significant finding is an increasing difference (conveniently expressed as a proportion) between the clotting times from the two plasmas.
SETTING UP THE TESTS It will be apparent that these tests may be run concurrently and the following plan is suggested:
(1) Obtain 10 ml. citrated blood from the patient and from a control subject: (2) set up the haematocrit of the patient's citrated blood, and also (3) the patient's platelet count, either on the venous or a capillary blood sample according to local practice. (4) Spin both the citrated bloods (say, 3,000 r.p.m. for 10 min.) to obtain citrated plasma. (5) Set up the fibrinogenolysis test and (6) take the initial readings to exclude heparinaemia; (7) set up the fibrinogen estimation and (8) take the next pair of readings from the fibrinogenolysis test; (9) do Quick's prothrombin time in the two plasmas; (10) repeat the fibrinogenolysis test; (11) examine the fibrinogen estimation tube and harvest the clot if it seems ready; (12) prepare the reagents for the Hicks and Pitney test and (13) repeat the fibroinogenolysis test if the rate of change in previous readings warrants it. It then only remains (14) to count the platelets, (15) perform the Hicks and Pitney test, (16) weigh the clot, and (17) repeat the fibrinogenolysis test in the most convenient order. The whole procedure takes an hour to an hour and a half, single handed.
Note that the following reagents may be maintained at -20°C., from which dilutions may be prepared for immediate use: (1) Human thrombin", approximately 50 units per ml., and (2) human fibrinogen, 1 g. per 100 ml. It has been found that the inclusion of a quarter-volume of the veronal buffer of Owren (1949) seems to prevent denaturation on repeated freezing and thawing. (3) The platelet substitute as a colloidal solution of Inosithin, I g. per 100 ml., or Bell and Alton's (1954) brain extract as described by the authors.
DISCUSSION
These tests are intended for laboratory use under the supervision of the clinical pathologist and are not bed-side tests (in the sense of tests to be performed by clinicians2) although they are simple enough to be done in a side-room equipped with a centrifuge, water bath, and the basic glassware. There is thus no mention of tests made on whole blood, such as the clotting time or the clot observation test, which are less efficient than the tests described in this paper and are only worth carrying out when laboratory facilities are not available.
The thrombin titre test of Sharp, Howie, Biggs, and Methuen (1958) is not mentioned because it is thought that the same information will be given by the test for fibrinogenolysis described above and that this test is more convenient to work in with other procedures which are proposed.
For the detection of a deficiency of AHG in the acquired bleeding states, the two-stage test of Hicks and Pitney is preferred to one-stage tests, e.g., of the type proposed by Margolis (1958) , because in the circumstances under discussion here, the one-stage tests might give abnormal results due to a deficiency of fibrinogen or even because prothrombin had become seriously depleted. These tests would therefore be difficult to interpret in terms of the early stages of blood coagulation which involve AHG. In the two-stage test, only the early phases of coagulation depend on materials supplied by the patient's plasma so that interpretation should be easier. 
